Cart
sales@molnova.com
ICAM-1-IN-1
CAS No. 251994-14-6
ICAM-1-IN-1( —— )
Catalog No. M26481 CAS No. 251994-14-6
ICAM-1-IN-1 is a potent and selective E-selectin(IC50 = 7 nM) and ICAM-1(IC50 = 5 nM) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 432 | In Stock |
|
| 5MG | 392 | In Stock |
|
| 10MG | 587 | In Stock |
|
| 25MG | 936 | In Stock |
|
| 50MG | 1237 | In Stock |
|
| 100MG | 1665 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 3339 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameICAM-1-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionICAM-1-IN-1 is a potent and selective E-selectin(IC50 = 7 nM) and ICAM-1(IC50 = 5 nM) inhibitor.
-
DescriptionICAM-1-IN-1 is a potent and selective E-selectin(IC50 = 7 nM) and ICAM-1(IC50 = 5 nM) inhibitor.(In Vivo):In a rat rheumatoid arthritis model and in a mouse asthma model, ICAM-1-IN-1 shows significant efficacy. The width of inflamed ankles after the ninth day following treatment was reduced by ICAM-1-IN-1, but no efficacy was shown in the acute phase. Treatment with ICAM-1-IN-1 (25 mg/kg) for 21 days significantly reduced eosinophils, serum-soluble ICAM-1 (sICAM-1) and the ankle inflammation of the arthritis rats.
-
In Vitro——
-
In VivoICAM-1-IN-1 shows significant efficacy in a rat rheumatoid arthritis model and in a mouse asthma model. ICAM-1-IN-1 reduces the width of inflamed ankles after the ninth day following treatment, but shows no efficacy in the acute phase. Treatment with ICAM-1-IN-1 (25 mg/kg) for 21 days significantly reduces the ankle inflammation of the arthritis rats. Significant reduction of eosinophils and serum-soluble ICAM-1 (sICAM-1) is observed.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorCDK4| CDK6
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number251994-14-6
-
Formula Weight363.23
-
Molecular FormulaC15H11BrN2O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 135 mg/mL (371.67 mM)
-
SMILESCNC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhang P, et al. A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. Biomark Res. 2021;9(1):24. Published 2021 Apr 12.
molnova catalog
related products
-
Cilengitide trifluor...
Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
-
Echistatin, α1 isofo...
Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) receptors (IC50 = 30 nM) in vitro.
-
A 286982
A 286982 is an inhibitor that blocks the integrin-ligand interaction between leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1.
